Long-term study of people with ATTR amyloidosis in routine care
Follows people with ATTR amyloidosis, including treatment with patisiran or vutrisiran.
Plain-language title generated from the registry record
Registry title: ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Key facts
- Where
- Groningen, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for people with ATTR amyloidosis, or people who carry a known disease-causing TTR variant but have no symptoms yet.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of ATTR amyloidosis, or a documented known disease-causing TTR variant for carriers without symptoms.
- Earlier treatment
- In Germany only, people must be treated as set out in the summary of product characteristics for an approved ATTR amyloidosis treatment.
- Biomarker or test result
- A documented known disease-causing TTR variant is needed for the group of carriers without symptoms.
Main reasons for not taking part
- Currently taking part in a clinical trial of any investigational agent
Read by machine on 12 November 2026.
Where in Netherlands
- GroningenHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT04561518
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
The purpose of this study is to:
* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Inclusion: Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers; Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis.
Exclusion: Current enrollment in a clinical trial for any investigational agent.